New connection sprouts between Alzheimer's disease and the immune system

May 31, 2017
High-resolution confocal images from the hippocampal CA3 region of Alzheimer's mouse brain show amyloid-beta plaques (green) and microglia/macrophages (red). Mice with complement C3 deficiency show an altered glial response to plaques. Credit: the Lemere Lab, Brigham and Women's Hospital

Just as trimming back the branches of an overgrown plant can encourage healthy growth, a little pruning of the connections in the human brain can be a good thing during brain development. But what happens when this natural process goes wrong later in life? Investigators at Brigham and Women's Hospital have found new clues from preclinical models to indicate that this "synaptic refinement" may play a role in neurodegenerative disease. Their findings, published in Science Translational Medicine, offer new insights into the interplay between the immune system and the development of Alzheimer's disease.

The new study looks at the role of complement C3 - a molecule involved in the immune response that is elevated in Alzheimer's . Previous studies have shown that C3 helps to trim back the connections between brain cells - known as synapses - during normal . Synapse loss occurs early in Alzheimer's disease and is associated with cognitive decline. Researchers have not known whether blocking the "complement cascade" - of which C3 is a central part - could protect against impairment and neurodegeneration at later stages of the disease. In the new study, the team examined the effects of C3 deficiency in a mouse model for Alzheimer's disease. The team found that mice with the engineered C3 deficiency were protected against age-related loss of synapses and and had fewer markers of inflammation in the brain.

Interestingly, they also find that in aged mice, the telltale amyloid plaques of Alzheimer's disease remain - and are even more abundant - but cognitive function improved: mice performed better on a learning and memory task, despite the accumulation of plaque in the .

High-resolution confocal images from a C3-sufficient mouse model of Alzheimer's disease show macrophages (red), microglia (green), amyloid-beta plaques (blue) and a composite image of all three. C3 deficiency partially suppressed the glial response to plaques. Credit: Lemere Lab, Brigham and Women's Hospital

"Amyloid plaque deposition occurs years before memory loss in Alzheimer's disease, but targeting how the immune system responds to these plaques could be an excellent therapeutic approach," said corresponding author Cynthia Lemere, PhD, of the Ann Romney Center for Neurologic Diseases at BWH. "We think that in later stages of the disease, it's not necessarily the plaques but the immune system's response to them that leads to neurodegeneration."

C3 has also been implicated in other central nervous system conditions, including stroke and macular degeneration. Although the current study is limited by the differences in the immune system and life span of mice and humans, the team's findings - and clues from previous studies - suggest that modulating complement signaling may represent a potential therapeutic strategy for combating Alzheimer's disease.

Explore further: Study reveals the possibility of curbing synapse loss in Alzheimer's

More information: DOI: 10.1126/scitranslmed.aaf6295 Q. Shi el al., "Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice," Science Translational Medicine (2017). http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aaf6295

Related Stories

Study reveals the possibility of curbing synapse loss in Alzheimer's

March 31, 2016
Researchers at Boston Children's Hospital show how brain connections, or synapses, are lost early in Alzheimer's disease and demonstrate that the process starts—and could potentially be halted—before telltale plaques ...

Alzheimer's disease researchers solve mystery of beguiling protein

February 6, 2017
Leading neuroscientists have clarified the role of a controversial immune system protein in Alzheimer's disease, showing it has opposing effects in early and late stages of the disease. Their discovery unites previous studies ...

Immune cells may protect against Alzheimer's

May 19, 2016
Clusters of immune cells in the brain previously associated with Alzheimer's actually protect against the disease by containing the spread of damaging amyloid plaques, a new Yale University School of Medicine study shows.

Blocking inflammation prevents cell death, improves memory in Alzheimer's disease

February 29, 2016
Using a drug compound created to treat cancer, University of California, Irvine neurobiologists have disarmed the brain's response to the distinctive beta-amyloid plaques that are the hallmark of Alzheimer's disease.

Experimental drug shows promise in treating Alzheimer's disease

October 25, 2016
An experimental drug shows promise in treating Alzheimer's disease by preventing inflammation and removing abnormal protein clumps in the brain that are associated with the disease, suggests a study in mice presented at the ...

Body's immune system may play larger role in Alzheimer's disease than thought

February 23, 2016
Immune cells that normally help us fight off bacterial and viral infections may play a far greater role in Alzheimer's disease than originally thought, according to University of California, Irvine neurobiologists with the ...

Recommended for you

Researchers reveal new details on aged brain, Alzheimer's and dementia

November 21, 2017
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that ...

Dementia study sheds light on how damage spreads through brain

November 20, 2017
Insights into how a key chemical disrupts brain cells in a common type of dementia have been revealed by scientists.

Study shows video games could cut dementia risk in seniors

November 16, 2017
Could playing video games help keep the brain agile as we age?

New player in Alzheimer's disease pathogenesis identified

November 14, 2017
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that a protein called membralin is critical for keeping Alzheimer's disease pathology in check. The study, published in Nature Communications, ...

Biomarker may predict early Alzheimer's disease

November 10, 2017
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a peptide that could lead to the early detection of Alzheimer's disease (AD). The discovery, published in Nature Communications, may ...

Smell test challenge suggests clinical benefit for some before development of Alzheimer's

November 10, 2017
Researchers at Columbia University Medical Center (CUMC) and the New York State Psychiatric Institute (NYSPI) may have discovered a way to use a patient's sense of smell to treat Alzheimer's disease before it ever develops. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.